Patient recruitment and retention continue to hamper clinical trials, causing delays in start up and forcing some studies to be cancelled altogether. Approximately 50 percent of trials have delays in recruitment, costing companies an estimated $600,000 per day. Even when recruitment is complete, 30 percent of patients, on average, will drop out of a trial. This costs companies even more money, delays the trial, and jeopardizes the data set. Pharma companies will overcome these difficulties only when they find ways to relieve the burden of trials.
Many industry experts believe the key to eliminating recruitment challenges is by companies taking a more patient-centric approach. But what exactly does patient-centric mean, and what are companies doing to better incorporate the patient voice into trial design and execution?
In this eBook, we attempt to present you with answers to those questions. Our experts from pharma discuss the actions you can and should be taking to make trials more patient-centric. Read about three ways to improve patient-centricity in your own trials. Learn how Eli Lilly, Merck, and Janssen are improving the patient experience by improving communication, increasing patient diversity in recruitment, and modifying trial design. John Whyte of WebMD and James Gillespie of Saint Mary’s College present an interesting analysis of how precision medicine is helping to bring patient-centricity to clinical trials.
We hope these articles will help you make your trials more patient-centric.